{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:18:24Z","timestamp":1792725504731,"version":"4.5.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Conventional type 1 dendritic cells (cDC1s) mastermind anti-cancer immunity and play a pivotal role in determining the efficacy of cancer immunotherapies. In this study, we sought to decipher the dynamic changes in the tumor immune landscape during intrahepatic cholangiocarcinoma (iCCA) development and harness the therapeutic potential of targeting cDC1s for cancer therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We constructed spontaneous murine iCCAs via hydrodynamic tail vein injection (HDTVi) of plasmids encoding AKT\/YAP. To characterize tumor-infiltrating immune cell populations throughout iCCA carcinogenesis and progression, we performed time-of-flight mass cytometry (CyTOF). To expand and activate cDC1s, we combined Flt3L with poly I:C (FL-pIC) therapy and assessed its therapeutic efficacy in both AKT\/YAP-induced iCCAs and a subcutaneous tumor injection model. Flow cytometric analyses were used to evaluate intra-tumoral infiltration levels of cDCs and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CyTOF analysis revealed the progressive formation of an immunosuppressive tumor microenvironment as iCCA advances. Crucially, infiltration of cDC1s dramatically decreases in advanced iCCAs compared to early-stage tumors. Combined FL-pIC therapy preferentially expanded CD103\n                      <jats:sup>+<\/jats:sup>\n                      cDC1s, powerfully inhibiting tumorigenesis in AKT\/YAP-driven murine iCCAs and sensitizing these tumors to anti-PD-1 therapy. Moreover, FL-pIC therapy markedly suppressed the growth of established mIC-23 subcutaneous tumors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our findings demonstrate that recruiting and activating intra-tumoral cDC1s is feasible and essential for driving anti-tumor CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell immune responses and enhancing anti-PD-1 therapeutic effectiveness in iCCA.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1708962","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:32:46Z","timestamp":1765521166000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Enhancing cDC1-mediated anti-tumor immunity limits tumor progression and potentiates anti-PD-1 therapy in intrahepatic cholangiocarcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Dong-Ni","family":"Pei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Xia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa-Zhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Dong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Ye","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"B3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12876-016-0527-z","article-title":"Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database","volume":"16","author":"Yao","year":"2016","journal-title":"BMC Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/s2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","article-title":"Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00859-1","article-title":"Dendritic cells as orchestrators of anticancer immunity and immunotherapy","volume":"21","author":"Heras-Murillo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev-immunol-020711-074950","article-title":"The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting","volume":"31","author":"Merad","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic cells and cancer immunity","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2017.07.022","article-title":"Oncogenic determination of a broad spectrum of phenotypes of hepatocyte-derived mouse liver tumors","volume":"187","author":"Yamamoto","year":"2017","journal-title":"Am J Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.037","article-title":"CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma","volume":"74","author":"Diggs","year":"2021","journal-title":"J Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05400-x","article-title":"Liver tumour immune microenvironment subtypes and neutrophil heterogeneity","volume":"612","author":"Xue","year":"2022","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/s41467-022-29164-0","article-title":"Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma","volume":"13","author":"Song","year":"2022","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","article-title":"Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma","volume":"40","author":"Dong","year":"2022","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.871769","article-title":"Dissecting intra-tumoral changes following immune checkpoint blockades in intrahepatic cholangiocarcinoma via single-cell analysis","volume":"13","author":"Sun","year":"2022","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s00432-024-05869-1","article-title":"Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma","volume":"150","author":"Sun","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1038\/s41467-020-19192-z","article-title":"Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s","volume":"11","author":"Oba","year":"2020","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41420-024-02079-z","article-title":"Mobilization and activation of tumor-infiltrating dendritic cells inhibits lymph node metastasis in intrahepatic cholangiocarcinoma","volume":"10","author":"Sun","year":"2024","journal-title":"Cell Death Discov"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.09.4565","article-title":"Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection","volume":"25","author":"Gao","year":"2007","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.immuni.2023.05.011","article-title":"Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses","volume":"56","author":"Bayerl","year":"2023","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41467-018-03600-6","article-title":"Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance","volume":"9","author":"Meyer","year":"2018","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccell.2020.02.008","article-title":"Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer","volume":"37","author":"Hegde","year":"2020","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0157-9","article-title":"Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma","volume":"24","author":"Auslander","year":"2018","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0249","article-title":"ICBatlas: A comprehensive resource for depicting immune checkpoint blockade therapy characteristics from transcriptome profiles","volume":"10","author":"Yang","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2025.03.023","article-title":"Prognostic significance of the cachexia index (CXI) in patients with cancer: A systematic review and meta-analysis","volume":"68","author":"Bas","year":"2025","journal-title":"Clin Nutr ESPEN"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2021.1864325","article-title":"BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care","volume":"15","author":"Rizzo","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/biology13050352","article-title":"Associations between \u201cCancer risk\u201d, \u201cInflammation\u201d and \u201cMetabolic syndrome\u201d: A scoping review","volume":"13","author":"Vitale","year":"2024","journal-title":"Biol (Basel)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.3390\/ijms231810869","article-title":"IDH inhibitors and immunotherapy for biliary tract cancer: A marriage of convenience","volume":"23","author":"Brandi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1137510","article-title":"Are FGFR and IDH1\u20132 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue","volume":"13","author":"Brandi","year":"2023","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0410-x","article-title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","volume":"25","author":"Hammerich","year":"2019","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30086-X","article-title":"Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study","volume":"4","author":"Ueno","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1708962\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:32:47Z","timestamp":1765521167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1708962\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2025.1708962"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1708962","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"article-number":"1708962"}}